Covalently immobilized thrombomodulin inhibits coagulation and complement activation of artificial surfaces in vitro

Biomaterials

Volumn 25, Issue 21, 2004, Pages 5101-5113

  Sperling, C ^a   Salchert, K ^a   Streller, U ^a   Werner, C ^a  

^a LEIBNIZ INSTITUTE OF POLYMER RESEARCH DRESDEN   (Germany)

Author keywords

Anticoagulant; Complement; Hemocompatibility; In vitro test; Platelet activation; Thrombomodulin

Indexed keywords

AMINO ACIDS; BLOOD; CHEMICAL ACTIVATION; COAGULATION; ENZYME IMMOBILIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROTEINS;

ENDOTHELIAL CELLS; THROMBOMODULIN;

BIOMATERIALS;

BLOOD CLOTTING FACTOR 12A; BRADYKININ; CARBOXYLIC ACID DERIVATIVE; COMPLEMENT COMPONENT C5A; ESTER DERIVATIVE; GLASS; HEPARIN; MACROGOL; MALEIC ANHYDRIDE; POLYMER; RECOMBINANT THROMBOMODULIN; THROMBOCYTE FACTOR 4;

ADULT; AMINO ACID ANALYSIS; ANTICOAGULATION; ARTICLE; BLOOD; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; COVALENT BOND; ELLIPSOMETRY; FILM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMOBILIZATION; IMMUNOFLUORESCENCE; IN VITRO STUDY; INCUBATION TIME; MATERIAL COATING; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SURFACE PROPERTY; THROMBOCYTE ACTIVATION;

ADSORPTION; ADULT; ANTICOAGULANTS; BLOOD COAGULATION; COATED MATERIALS, BIOCOMPATIBLE; COMPLEMENT ACTIVATION; HUMANS; MATERIALS TESTING; POLYMERS; SURFACE PROPERTIES; THROMBOMODULIN;

EID: 1942454381     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2003.12.014     Document Type: Article

References (91)

1. Teebken O.E., Haverich A. Tissue engineering of small diameter vascular grafts. Eur J Vasc Endovasc Surg. 23(6):2002;475-485.
2. Machovich R. Blood vessel wall and thrombosis. Boca Raton: CRC Press; 1988. p. 5.
3. Jaffe E.A. Biochemistry, Immunology and Cell Biology of Endothelium. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Blood vessels in hemostasis and thrombosis. 1994;718-744 Lippincott Company, Philadelphia.
4. Diquelou A., Dupouy D., Gaspin D., Constans J., Sié P., Boneu B., Sakariassen K.S., Cadroy Y. Relationships between endothelial tissue factor and thrombogenesis under blood flow conditions. Thromb Haemost. 74:1995;778.
5. Giesen P.L.A., Rauch U., Bohrmann B., Kling D., Roqué M., Fallon J.T., Badimon J.J., Himber J., Riederer M.A., Nemerson Y. Blood-borne tissue factor. another view of thrombosis Proc Natl Acad Sci. 96:1999;2311-2315.
6. Balasubramanian V., Grabowski E., Bini A., Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi. real-time fluorescence images of thrombus formation and propagation under defined flow conditions Blood. 100:2002;2787-2792.
7. Zilla P, Greisler HP (Hrsg.). Tissue engineering of vascular prosthetic grafts. R.G. Landes Company; Austin; 1999.
8. Bordenave L., Remy-Zolghadri M., Fernandez P., Bareille R., Midy D. Clinical performance of vascular grafts lined with endothelial cells. Endothelium. 6(4):1999;267-275.
9. Zilla P. Endothelialization of vascular grafts. Curr Opin Cardiol. 6(6):1991;877-886.
10. Wendel H.P., Ziemer G. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Europ J Cardio-thorac Surg. 16:1999;342-350.
11. Jansen P.G.M., te Velthuis H., Huybregts R.A., Paulus R., Bulder E.R., van der Spoel H.I., Bezemer P.D., Slaats E.H., Eijsman L., Wildevuur C.R.H. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg. 110:1995;829-834.
12. Belboul A., al-Khaja N. Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery. Perfusion. 12:1997;385-391.
13. Belboul A., Lofgren C., Storm C., Jungbeck M. Heparin-coated circuits reduce occult myocardial damage during CPB. a randomized, single blind clinical trial Eur J Cardiothorac Surg. 17:2000;580-586.
14. Tamim M., Demircin M., Guvener M., Peker O., Yilmaz M. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass. Panminerva Med. 41:1999;193-198.
15. Schreurs H.H., Wijers M.J., Gu Y.J., van Oeveren W., von Domburg R.T., de Boer J.H., Bogers A.J. Heparin-coated bypass circuits. effects on inflammatory response in pediatric cardiac operations Ann Thorac Surg. 66:1998;166-171.
16. Johnell E., Elgue G., Larsson R., Larsson A., Thelin S., Siegbahn A. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J Thorac Cardiovasc Surg. 124(2):2002;321.
17. Blezer R., Fouache B., Willems G.M., Lindhout T. Activation of blood coagulation at heparin-coated surfaces. J Biomed Mater Res. 37:1997;108-113.
18. Ohshiro T., Liu M.C., Kambayashi J., Mori T. Clinical applications of urokinase-treated material. Methods in Enzymology. 137:1988;529-545.
19. Yabushita Y., Suyama K., Takagi K. Studies on properties of immobilized urokinase. Chem Pharm Bull. 36:1988;954-958.
20. Ryu G.H., Park S.Y., Cho H.I., Min B.G. Enhancement of antithrombogenicity by urokinase immobilization on the gelatin-adsorbed polyurethane surface. The Seoul J Med. 30(1):1989;37-46.
21. Sugitachi A., Takagi K. Antithrombogenicity of immobilized urokinase - clinical applications. Int J Artif Organs. 1:1978;88-92.
22. Aoshima R. Sulfonated poly (vinylidene fluoride) as a biomaterial. immobilization of urokinase and biocompatibility J Biomed Mater Res. 16:1982;289-299.
23. Kitamoto Y., Tomita M., Kiyama S., Inoue T., Yabushita Y., Sato T., Ryoda H., Sato T. Antithrombotic mechanisms of urokinase immobilized polyurethane. Thromb Haemost. 65:1991;73-76.
24. Ohshiro T., Kosaki G. Urokinase immobilized on medical polymeric materials. fundamentals and clinical studies Artif Org. 4:1980;58-64.
25. Bohl K.S., West J.L. Nitric oxide generating polymers reduce platelet adhesion and smooth muscle cell proliferation. Biomaterials. 21:2000;2273-2278.
26. 2 plasma-initiated vapour phase graft polymerization of acrylic acid onto polytetrafluoroethylene for immobilization of human thrombomodulin. Biomaterials. 18(17):1997;1139-1145.
27. Sperling C., König U., Hermel G., Werner C., Müller M., Simon F., Grundke K., Jacobasch H.J. Immobilization of human thrombomodulin onto PTFE. J Mater Met: Mater Med. 8:1997;789-791.
28. Esmon C.T. The regulation of natural anticoagulant pathways. Science. 235:1987;1348-1352.
29. Maruyama I. Thrombomodulin, an endothelial anticoagulant; its structure, function and expression. Jpn Circ J. 56:1992;187-191.
30. Esmon N.L. Thrombomodulin. Prog Hemost Thromb. 9:1989;29-55.
31. Maruyama I., Majerus P.W. The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial celss and A549 lung cancer cells. J Biol Chem. 260:1985;15432-15438.
32. Califano F., Giovanniello T., Pantone P., Campana E., Parlapiano F. Clinical importance of thrombomodulin serum levels. Eur Rev Med Pharmacol Sci. 4:2000;59-66.
33. Wood M.J., Benitez B.A.S., Komives E.A. Solution structure of the smallest cofactor-active fragment of thrombomodulin. Nat Struct Biol. 7(3):2000;200-204.
34. Fuentes-Prior P., Iwanaga Y., Huber R., Pagila R., Rumennik G., Seto M., Morser J., Light D., Bode W. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature. 404:2000;518-525.
35. Esmon C.T. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 9:1995;946-955.
36. Esmon C.T. Regulation of blood coagulation. Biochim Biophys Acta. 1477(1-2):2000;349-360.
37. Krishnaswamy W., Williams E.B., Mann K.G. The binding of activated protein C to factor V and Va. J Biol Chem. 261:1986;9684-9693.
38. Walker F.J., Fay P.J. Regulation of blood coagulation by the protein C system. FASEB J. 6:1992;2561-2567.
39. Dittman W.A. Thrombomodulin - biology and potential cardiovascular applications. Trends Cardiovasc Med. 1:1991;331-336.
40. Esmon C.T., Taylor F.B., Snow T.R. Inflammation and coagulation. linked processes potentially regulated through a common pathway mediated by protein C Thromb Haemost. 66(1):1991;160-165.
41. Nesheim M., Wang W., Boffa M., Nagashima M., Morser J., Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 78:1997;386-391.
42. Dhainaut J.F., Yan S.B., Cariou A., Mira J.P. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit Care Med. 30:2002;S318-S24.
43. Broze G.J., Miletich J.P. Biochemistry and physiology of protein C, protein S and thrombomodulin. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and thrombosis. 1994;259-276 Lippincott Company, Philadelphia.
44. Mosnier L., Meijers J., Bouma B. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost. 85:2001;1-2.
45. Sakata Y., Curriden S., Lawrence D., Griffin J.H., Loskutoff D.J. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA. 82:1985;1121-1125.
46. Han H.S., Wu H.L., Lin B.T., Shi C.S., Shi G.Y. Effect of thrombomodulin on plasminogen activation. Fibrinolysis Proteolysis. 14:2000;221-228.
47. Hirsh J. Current anticoagulant therapy - unmet clinical needs. Thromb Res. 109:2003;S1-S8.
48. Kishida A., Ueno Y., Maruyama I., Akashi M. Immobilization of human thrombomodulin on biomaterials. evaluation of the activity of immobilized human thrombomodulin Biomaterials. 15(14):1994;1170.
49. Yagi K., Kouichi H., Yamasaki S., Uwai A., Miura Y. Anticoagulant activity of immobilized thrombomodulin. Chem Pharm Bull. 37(3):1989;732.
50. Han H-.S., Yang S-.L., Yeh H-.Y., Lin J-.C., Wu H-.L., Shi G-.Y. Studies of a novel human thrombomodulin immobilized substrate. surface characterization and anticoagulation activity evaluation J Biomater Sci Polym Edn. 12:2001;1075-1089.
51. Kishida A., Ueno Y., Maruyama I., Akashi M. Immobilization of human thrombomodulin onto biomaterials. ASAIO J. 40:1994;840-845.
52. Li J.M., Singh M.J., Nelson P.R., Hendricks G., Itani M., Rohrer M.J., Cutler B.S. Immobilization of human thrombomodulin to expanded polytetrafluoroethylene. J Surg Res. 105:2002;200.
53. Kishida A., Ueno Y., Fukudome N., Yashima E., Maruyama I., Akashi M. Immobilization of human thrombomodulin onto poly(ether urethane urea) for developing antithrombogenic blood-contacting materials. Biomaterials. 15(10):1994;848-852.
54. Streller U., Sperling C., Hübner J., Hanke R., Werner C. Design and evaluation of novel blood incubation systems for in vitro hemocompatibility assessment of planar solid surfaces. J Biomed Mater Res Part B: Appl Biomater 66b, 1:2003;379-390.
55. Hollemann AF, Wiberg E. Lehrbuch der anorganischen Chemie. Berlin: de Gruyter; 1985. p. 754-5.
56. Schmidt U., Zschoche S., Werner C.J. Modication of poly(octadecene-alt- maleic anhydride) films by reaction with functional amines. Appl Polym Sci. 87:2003;1255-1266.
57. Pompe T., Zschoche S., Herold N., Salchert K., Gouzy M.F., Sperling C., Werner C. Maleic anhydride copolymers - a versatile platform for molecular biosurface engineering. Biomacromolecules. 4:2003;1072-1079.
58. Salchert K., Pompe T., Sperling C., Werner C. Quantitative analysis of immobilized proteins and protein mixtures by amino acid analysis. J Chromatogr A. 1005:2003;113-122.
59. Deveny T, Gergely G. (Hrsg.). Hydrolysis of proteins and peptides. Amino Acids Peptides Proteins 1974;162-4.
60. Meltzer N.M., Guillermo I.T., Gruber S., Stein S. Gas-phase hydrolysis of proteins and peptides. Anal Biochem. 160:1987;356-361.
61. Jones B.N., Pääbo S., Stein S. Amino acid analysis and enzymatic sequence determination of peptides by an improved o-phthaldialdehyde percolumn labeling procedure. J Liq Chrom. 4:1981;565-586.
62. Edens R.E., Linhardt R.J., Weiler J.M. Heparin is not just an anticoagulant anymore. six and one-half decades of studies on the ability of heparin to regulate complement activity Complement Today Compl Profiles. 1:1993;96-120.
63. Sissener Engstad C., Gutteberg T.J., Osterud B. Modulation of blood cell activation by four commonly used anticoagulants. Thromb Haemost. 77:1997;690-696.
64. Sissener Engstad C., Gutteberg T.J., Osterud B. Modulation of blood cell activation by four commonly used anticoagulants. Thromb Haemost. 77:1997;690-696.
65. Barret R.A., Butler K.D., Morley J., Page C.P., Paul W., White A.M. Inhibition by heparin of platelet accumulation in vivo. Thromb Haemost. 51:1984;366-370.
66. Edens R.E., Linhardt R.J., Weiler J.M. Heparin is not just an anticoagulant anymore. six and one-half decades of studies on the ability of heparin to regulate complement activity Compl Today Compl Profiles. 1:1993;96-120.
67. Rosenbauer KHA, Kegel BH. Rasterelektronenmikroskopische Technik, Stuttgart: Georg Thieme Verlag; 1978. p. 30-3, 51-5, 59-64.
68. Suzuki K., Kusumoto H., Deyashiki Y., Nishioka J., Maruyama I., Zushi M., Kawahara S., Honda G., Yamamoto S., Horiguchi S. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J. 6:1987;1891-1897.
69. Wen D., Dittman W.A., Ye R.D., Deaven L.L., Majerus P.W., Sadler J.E. Human thrombomodulin. complete cDNA sequence and chromosome localization of the gene Biochemistry. 26:1987;4350-4357.
70. Kurosawa S., Stearns D.J., Jackson K., Esmon C.T. A 10. kDa cyanogen bromide fragment from the epidermal growth factor homology domain of rabbit thrombomodulin contains the primary thrombin binding site J Biol Chem. 263:1988;5993-5996.
71. De Cristofaro R., De Candia E., Landolfi R. Effect of high- and low-molecular-weight heparins on thrombin-thrombomodulin interaction and protein C activation. Circulation. 98:1998;1297-1301.
72. Verresen L., Fink E., Lemke H.D., Vanreterghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int. 45:1994;1497-1503.
73. Colman R.W. Surface-mediated defense reactions. J Clin Invest. 73:1984;1249-1253.
74. Yarovaya G.A., Blokhina T.B., Neshkova E.A. Contact system. New concepts on activation mechanisms and bioregulatory functions. Biochemistry (Moscow). 67:2002;16-29.
75. Colman R.W., Schmaier A.H. Contact system. a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes Blood. 90:1997;3819-3843.
76. Vogler E.A., Graper J.C., Harper G.R., Sugg H.W., Lander L.M., Brittain W.J. Contact activation of the plasma coagulation cascade. I. Procoagulant surface chemistry and energy. J Biomed Mater Res. 29:1995;1005-1016.
77. Groth T., Synowitz J., Malsch G., Richau K., Albrecht W., Lange K-.P., Paul D. Contact activation of plasmatic coagulation on polymeric membranes measured by the activity of kallikrein in heparinized plasma. J Biomater Sci Polym Edn. 8:1997;797-807.
78. Deible C.R., Petrosko P., Johnson P.C., Beckman E.J., Russell A.J., Wagner W.R. Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol. Biomaterials. 20:1999;101-109.
79. Fushimi F., Nakayama M., Nishimura K., Hiyoshi T. Platelet adhesion, contact phase activation, and C5a generation of polyethylene glycol acid-grafted high flux cellulosic membrane with varieties of grafting amounts. Art Organs. 22:1998;821-826.
80. Minnema M., Ten Cate H., Hack C. The role of factor XI in coagulation. a matter of revision Semin Thromb Hemost. 25:1999;419-428.
81. Mattson C., Menschik-Lundin A., Nylander S., Gyzander E., Deinum J. Effect of different types of thrombin inhibitors on the thrombin/thrombomodulin modulated activation of protein C in vitro. Thromb Res. 104:2001;475-486.
82. Jansen P.M., Pixley R.A., Brouwer M., de Jong I.W., Chang A.C., Hack C.E., Taylor F.B., Colman R.W. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood. 87:1996;2337-2344.
83. Kidane A., Park K. Complement activation by PEO-grafted glass surfaces. J Biomed Mater Res. 48:1999;640-647.
84. Labarre D., Laurent A., Lautier A., Bouhni S., Kerbellec L., Lewest J.M., Tersinet N. Complement activation by substituted polyacrylamide hydrogels for embolisation and implantation. Biomaterials. 23:2002;2319-2327.
85. Campbell W.D., Lazoura E., Okada N., Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol. 46(2):2002;131-134.
86. Schaiff W.T., Eisenberg P.R. Direct induction of complement activation by pharmacologic activation of plasminogen. Coron Artery Dis. 8:1997;9-18.
87. Grey S.T., Tsuchida A., Hau H., Orthner C.L., Salem H.H., Hancock W. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol. 153:1994;3664-3672.
88. Murakami K., Okajima K., Uchiba M., Johno M., Nakagaki T., Okabe H., Takatsuki K. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 87:1996;642-647.
89. White B., Schmidt M., Murphy C., Livingstone W., O'Toole D., Lawler M., O'Neill L., Kelleher D., Schwarz H., Smith O. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappa B) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol. 110:2000;130-134.
90. Li J., Garnette C., Cahn M., Claytor R., Rohrer M., Dobson J., Gerlitz B., Cutler B. Recombinant thrombomodilin inhibits arteria smooth muscle cell proliferation induced by thrombin. J Vasc Surg. 32:2000;804-813.
91. Philippou H, Rance J, Myles T, Hall SW, Ariens RA, Grant PJ, Leung L, Lane DA. Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation: competition for cofactor sites on thrombin determines its fate. J Biol Chem 2003, published online June 06.